Related Experiment Video
Updated: Feb 17, 2026
14:48
Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
5.6K
Pentoxifylline in severe inflammatory response syndrome
1Department of Infectious Diseases, University Hospital of Vienna, Austria.
Journal of Cardiovascular Pharmacology
|January 1, 1995
Summary
Pentoxifylline (PTX) shows potential anti-inflammatory effects for sepsis and severe inflammatory response syndrome (SIRS). However, optimal dosing, adverse effects, and its role in complex inflammatory conditions require further research.
Area of Science:
- Immunology
- Pharmacology
- Critical Care Medicine
Background:
- Sepsis induces a complex inflammatory response with significant pathophysiological changes.
- Severe Inflammatory Response Syndrome (SIRS) is characterized by an exaggerated immune response.
- Pentoxifylline (PTX), a methylxanthine, exhibits selective anti-inflammatory properties.
Purpose of the Study:
- To evaluate the potential of Pentoxifylline (PTX) as a modulator of SIRS.
- To review the existing evidence and suggest considerations for future clinical trials.
Main Methods:
- Review of animal studies and human clinical data on Pentoxifylline's efficacy and safety.
- Analysis of PTX's mechanism of action, particularly its effect on tumor necrosis factor (TNF) and neutrophil activity.
- Consideration of factors for clinical trial design, including dose-response, disease severity, and pathogens.
Main Results:
- PTX has shown promise in conditions like human malaria and other hyper-TNF states.
- The effective dosage and optimal use of PTX remain unclear.
- Potential adverse effects include depression of TNF expression and impaired neutrophil function.
Conclusions:
- PTX may offer benefits in managing inflammatory conditions like SIRS, but its efficacy and safety profile require further investigation.
- Careful planning of randomized clinical trials is essential, considering various factors.
- A single agent is unlikely to be a cure for sepsis; combination therapies may be necessary, posing economic and ethical challenges.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
536
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
536
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
561
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
561
01:29Inflammatory Bowel Disease IV: Pharmacological Management
795
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
795
01:24Antiasthma Drugs: Methylxanthines
1.7K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.7K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
600
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
600
01:29Drugs for Treatment of Ulcerative Colitis in IBD
544
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
544